Prescription Drugs - Research and Data from KFF

What to Watch in 2024: The Latest Health Cost and Affordability Issues and Trends

Jan 24, 2024

News Release

While issues of health care costs and affordability may not be at the forefront of this year’s election issues, they remain a major concern among the public. About a quarter of Americans say they or a family member struggled to pay their medical bills just in the past year, and in recent KFF polling, voters said that health care affordability was very important to discuss in the election.KFF’s new brief describes the health cost and…

Year in Review: 10 Health Policy Issues for 2023

Dec 22, 2023

Fact Sheet

This fact sheet offers a look back at 10 issues that KFF tracked closely during 2023 in its polling, policy analysis and journalism, including summaries of major findings and news stories.

Poll: By a Wide Margin, Democratic Voters Now Care More About the Affordable Care Act Than Republican Voters Do, And Voters Trust Democrats More Than Republicans to Handle Its Future

Dec 1, 2023

News Release

The future of the Affordable Care Act, an issue that was once a key health care issue for Republican voters, is now more important to Democratic voters, a new KFF Health Tracking Poll finds. About half (49%) of voters say it is a “very important” issue for the candidates to discuss, including more than twice the share of Democratic voters (70%) than Republican voters (32%). Fielded prior to former President Donald Trump’s recent social media…

KFF Health Tracking Poll: Health Care Issues Emerge as Important Topics on 2024 Campaign Trail, Plus Concerns Loom Large Around Medicaid Unwinding

Dec 1, 2023

Feature

The future of the Affordable Care Act, once a key issue for Republican voters, is now of higher importance to Democratic voters. This KFF Health Tracking Poll also explores other important issues for candidates to discuss according to voters, Medicaid unwinding, Medicare drug-price provisions, and abortion as a voting issue.

More Than Six in Ten Large Firms Say GLP-1 Drug Coverage for Weight Loss Moderately or Significantly Impacted Their Prescription Drug Spending

Perspectives from Employers on the Costs and Issues Associated with Covering GLP-1 Agonists for Weight Loss

Oct 22, 2025

Issue Brief

While more large employers are covering GLP-1 drugs for weight loss, KFF's conversations with employers highlight concerns about the cost of these medications. Many of these employers have considered scaling back coverage of GLP-1 agonists for weight loss, or in some cases, employers are adding or strengthening coverage requirements.

Changes to Medicare Part D in 2024 and 2025 Under the Inflation Reduction Act and How Enrollees Will Benefit

Apr 20, 2023

Issue Brief

The Inflation Reduction Act of 2022 includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, including a number of changes to the Medicare Part D drug benefit. This brief provides an overview of the Part D benefit design and Part D enrollee cost-sharing requirements in 2023 and changes coming in 2024 and 2025.

Examining Short-Term Limited-Duration Health Plans on the Eve of ACA Marketplace Open Enrollment

Oct 15, 2025

Issue Brief

As Marketplace Open Enrollment nears, policy changes could leave millions of people facing substantially higher premiums and coverage loss, which could lead more consumers to purchase less expensive and less comprehensive coverage through short-term health plans. KFF analyzes short-term health policies sold by nine large insurers in 36 states, examining premiums, cost sharing, covered benefits, and coverage limitations and comparing them to ACA Marketplace plans.

Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity

Nov 26, 2024

Policy Watch

This policy watch examines the implications of new proposed regulations that would allow Medicare and require Medicaid to cover drugs used to treat obesity, including a relatively new class of highly effective but costly drugs known as GLP-1s.

While Medicare Drug Price Negotiations Don’t Apply to Private Insurance, 3.4 Million People with Employer Coverage Take at Least One of the Selected Drugs

Aug 14, 2024

News Release

Among the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations.

Medicare Advantage 2026 Spotlight: A First Look at Plan Offerings

Dec 9, 2025

Issue Brief

This brief provides an overview of the Medicare Advantage plans that are available for 2026 and key trends over time. In 2026, the average Medicare beneficiary has a choice of 32 Medicare Advantage prescription drug (MA-PD) plans, two fewer than the 34 in 2025. Virtually all Medicare Advantage plans for 2026 provide multiple extra benefits like vision, hearing, and dental benefits, similar to last year.

Topics

Policy Research

Polling

Health News

Data & Features

For Media

About

View the Latest: Prescription Drugs

Filter